相似文献
1
Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.
Circ Heart Fail. 2020 Feb;13(2):e006623. doi: 10.1161/CIRCHEARTFAILURE.119.006623. Epub 2020 Feb 14.
2
The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
Circulation. 2017 Oct 17;136(16):1459-1461. doi: 10.1161/CIRCULATIONAHA.117.029284.
3
Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in type 2 diabetes: A systematic review and meta-analysis.
Eur J Prev Cardiol. 2020 Apr;27(6):667-670. doi: 10.1177/2047487319841936. Epub 2019 Apr 9.
4
Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
Curr Vasc Pharmacol. 2019;17(4):421-424. doi: 10.2174/1570161116666180831124717.
5
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.
6
Cost-Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in China: A New Pillar in Our Pockets, but at What Price?
J Cardiovasc Pharmacol. 2024 Jan 1;83(1):43-45. doi: 10.1097/FJC.0000000000001498.
7
Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
Circulation. 2019 Jan 8;139(2):152-154. doi: 10.1161/CIRCULATIONAHA.118.037599.
8
Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
Cardiovasc Diabetol. 2021 Jun 28;20(1):130. doi: 10.1186/s12933-021-01316-4.
9
Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure.
Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719894509. doi: 10.1177/1753944719894509.
10
Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?
Expert Rev Clin Pharmacol. 2019 Aug;12(8):693-695. doi: 10.1080/17512433.2019.1635453. Epub 2019 Jun 30.
引用本文的文献
1
Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization.
US Cardiol. 2021 Apr 23;15:e07. doi: 10.15420/usc.2020.29. eCollection 2021.
2
Ginseng Radix et Rhizoma enhanced the effect of metoprolol in chronic heart failure by inhibiting autophagy in male C57BL/6J mice.
PLoS One. 2024 Aug 14;19(8):e0301875. doi: 10.1371/journal.pone.0301875. eCollection 2024.
3
Effectiveness of Yiqi Fumai lyophilized injection for acute heart failure: Rationale and design of the AUGUST-AHF cohort study.
Front Cardiovasc Med. 2023 Jan 10;9:1074406. doi: 10.3389/fcvm.2022.1074406. eCollection 2022.
4
Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia.
Cureus. 2022 Apr 19;14(4):e24284. doi: 10.7759/cureus.24284. eCollection 2022 Apr.
5
Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction.
ESC Heart Fail. 2022 Apr;9(2):800-811. doi: 10.1002/ehf2.13811. Epub 2022 Feb 3.
6
Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction.
CJC Open. 2021 Feb 1;3(5):646-657. doi: 10.1016/j.cjco.2021.01.006. eCollection 2021 May.
7
What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Curr Diab Rep. 2020 Oct 11;20(11):63. doi: 10.1007/s11892-020-01347-3.
8
Weighted gene co-expression network analysis to define pivotal modules and genes in diabetic heart failure.
Biosci Rep. 2020 Jul 31;40(7). doi: 10.1042/BSR20200507.
本文引用的文献
1
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
2
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486.
3
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. doi: 10.1016/S2213-8587(19)30256-6. Epub 2019 Sep 5.
4
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
5
Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists.
JACC Heart Fail. 2019 Feb;7(2):169-172. doi: 10.1016/j.jchf.2018.11.013.
6
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
J Am Coll Cardiol. 2018 Dec 18;72(24):3200-3223. doi: 10.1016/j.jacc.2018.09.020. Epub 2018 Nov 26.
7
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.
8
Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.
JACC Heart Fail. 2019 Jan;7(1):1-12. doi: 10.1016/j.jchf.2018.06.011. Epub 2018 Nov 7.
9
Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling.
J Am Coll Cardiol. 2018 Dec 25;72(25):3370-3372. doi: 10.1016/j.jacc.2018.08.2202.
10
Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
J Am Coll Cardiol. 2018 Jul 24;72(4):351-366. doi: 10.1016/j.jacc.2018.04.070.
Zotero 插件